Inspection Record

Central Admixture Pharmacy Services Inc. — FDA 483 Findings

US FDAInspected 2016-02-25Published 2024-01-17 5 findingsTraining and personnelAseptic processing and sterility assuranceLaboratory and QC controlsEquipment and facility

Inspectors Nicholas L Paulin · Michael P SheehanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

2Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile do not include adequate validation ofthe sterilization process.

3Laboratory and QC controls

( ­ Testing and release of drug product for distribution.do not include appropriate laboratory determination ofsatisfactory conformance to the final specifications prior to release.

4Equipment and facility

Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

5Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Central Admixture Pharmacy Services Inc. findings history — including this company's other documents US FDA documents, 2024 Go to Findings search